David W. Cescon, Tiffany A. Traina, Peter Schmid, Javier Cortés, Zhimin Shao, Shigehira Saji, Kyung Hae Jung, Thomas Bachelot, Shouman Wang, Emilio Murillo Ramírez, Gül Başaran, Yee Soo Chae, Agostina Stradella, Rofhiwa Mathiba, Shin-Cheh Chen, Nicola Battelli, Naoki Niikura, Kechen Zhao, Micah J. Maxwell, Rebecca Alexandra Dent. "First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.1002